Literature DB >> 19804091

Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart.

E Ann Tallant1, Carlos M Ferrario, Patricia E Gallagher.   

Abstract

Angiotensin-(1-7), a biologically active peptide of the renin-angiotensin system, is cardioprotective following ischemia/reperfusion and reduces cardiac hypertrophy. A recently discovered homolog of angiotensin converting enzyme (ACE), ACE2, is present in the heart and synthesizes angiotensin-(1-7) from angiotensin II. Cardiac ACE2 is elevated following inhibition of Ang II subtype 1 (AT(1)) receptors or blockade of angiotensin II production, suggesting that angiotensin-(1-7) plays a role in the beneficial effects of AT(1) receptor antagonists and ACE inhibitors in the heart. An increase in ACE2 activity and the production of angiotensin-(1-7) may thus represent a novel therapy for heart failure following myocardial infarction.

Entities:  

Year:  2006        PMID: 19804091     DOI: 10.2217/14796678.2.3.335

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  9 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

3.  Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.

Authors:  Vijayakumar Sukumaran; Punniyakoti T Veeraveedu; Narasimman Gurusamy; Ken'ichi Yamaguchi; Arun Prasath Lakshmanan; Meilei Ma; Kenji Suzuki; Makoto Kodama; Kenichi Watanabe
Journal:  Int J Biol Sci       Date:  2011-09-08       Impact factor: 6.580

Review 4.  Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Leanne Groban
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

Review 5.  COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.

Authors:  Mohamed M Aboudounya; Richard J Heads
Journal:  Mediators Inflamm       Date:  2021-01-14       Impact factor: 4.711

6.  Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy.

Authors:  Yumei Feng; Chetan Hans; Elizabeth McIlwain; Kurt J Varner; Eric Lazartigues
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

7.  Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice.

Authors:  Maira Soto; Nicole Delatorre; Chelsie Hurst; Kathleen E Rodgers
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

8.  Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.

Authors:  David N Deaton; Enoch N Gao; Kevin P Graham; Jeffrey W Gross; Aaron B Miller; John M Strelow
Journal:  Bioorg Med Chem Lett       Date:  2007-11-19       Impact factor: 2.823

9.  Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.

Authors:  David N Deaton; Kevin P Graham; Jeffrey W Gross; Aaron B Miller
Journal:  Bioorg Med Chem Lett       Date:  2008-01-18       Impact factor: 2.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.